Company: KROS
Filing Date: 2025-05-19
Form Type: DEFA14A
Source: 0001104659-25-050243
Chunk: 4

Company: Keros Therapeutics, Inc.
Filing Date: 2025-05-19
Form: DEFA14A
Chunk 4
---
, its director nominees
and certain of its executive officers and employees may be deemed to be participants in the solicitation of proxies for the Annual Meeting.
Information regarding the names of such persons and their respective direct or indirect interests in the Company, by securities holdings
or otherwise, is available in the Proxy Statement, which was filed with the SEC on April 23, 2025, including in the sections captioned
“Compensation Discussion and Analysis,” “Executive Compensation” “Non-Employee Director Compensation,”
“Transactions with Related Persons and Indemnification” and “Security Ownership of Certain Beneficial Owners and Management.”
To the extent that the Company’s directors and executive officers have acquired or disposed of securities holdings since the applicable
“as of” date disclosed in the Proxy Statement, such transactions have been or will be reflected on Statements of Changes in
Ownership of Securities on Form 4 or Initial Statements of Beneficial Ownership of Securities on Form 3 filed with the SEC.
These documents are or will be available free of charge at the SEC’s website at www.sec.gov.